Chemotherapy News and Research

Latest Chemotherapy News and Research

Study explores impact of chemotherapy on breast cancer survivors’ employment

A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received.

29 Apr 2014

Mayo Clinic launches new gene panel cancer test to help tailor chemotherapy

Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor.

29 Apr 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Women who had chemotherapy less likely to be employed 4 years later

Nearly one-third of breast cancer survivors who were working when they began treatment were unemployed four years later. Women who received chemotherapy were most affected, according to a new study from the University of Michigan Comprehensive Cancer Center.

28 Apr 2014

New study sheds light on mysterious gene that influences cardiovascular health

A new study from researchers at the University of Ottawa Heart Institute (UOHI), published today in Cell Reports, sheds light on a mysterious gene that likely influences cardiovascular health.

26 Apr 2014

Promising new approach targets cancer protein to slow tumor growth

Sometimes a full-on assault isn't the best approach when dealing with a powerful enemy. A more effective approach, in the long run, may be to target the support system replenishing the supplies that keep your foe strong and ready for battle.

26 Apr 2014

MIT researchers develop test that can rapidly assess DNA repair systems

Our DNA is under constant attack from many sources, including environmental pollutants, ultraviolet light, and radiation. Fortunately, cells have several major DNA repair systems that can fix this damage, which may lead to cancer and other diseases if not mended.

25 Apr 2014

Variant of cell surface protein may help develop drugs for gastric cancer

A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.

25 Apr 2014

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

25 Apr 2014

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Approximately 15 percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy. However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.

25 Apr 2014

ASTRO’s guideline details use of adjuvant radiation therapy in treatment of endometrial cancer

The American Society for Radiation Oncology (ASTRO) has issued a new guideline, "The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that details the use of adjuvant radiation therapy in the treatment of endometrial cancer.

25 Apr 2014

Research shows why breast cancer often metastasizes to lung

New research led by Alison Allan, PhD, a scientist at Western University and the Lawson Health Research Institute, shows why breast cancer often spreads or metastasizes to the lung.

25 Apr 2014

Roche's cobas HPV Test gets FDA approval for first-line primary screening for cervical cancer

Roche announced today that the U.S. Food and Drug Administration approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12 unanimous recommendation from the Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee, making the cobas HPV Test the first and only HPV test in the United States approved for first-line primary screening.

From Roche Sequencing and Life Science 25 Apr 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

23 Apr 2014

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

New study by the Cancer Science Institute of Singapore and National University Hospital Singapore suggests that a variant of a cell surface protein is an ideal target for developing drugs to treat gastric cancer

23 Apr 2014

SIOG, EORTC update expert opinion on managing treatment for aged patients with NSCLC

Half of all patients diagnosed with non-small cell lung cancer are 70 years of age or older, yet despite this high percentage, these elderly patients are not well represented in clinical trials. Therefore, the paucity of clinical data has made it difficult to reach evidence based clinical recommendations.

23 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Study explores impact of chemotherapy on breast cancer survivors’ employment

Mayo Clinic launches new gene panel cancer test to help tailor chemotherapy

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Women who had chemotherapy less likely to be employed 4 years later

New study sheds light on mysterious gene that influences cardiovascular health

Promising new approach targets cancer protein to slow tumor growth

MIT researchers develop test that can rapidly assess DNA repair systems

Variant of cell surface protein may help develop drugs for gastric cancer

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

ASTRO’s guideline details use of adjuvant radiation therapy in treatment of endometrial cancer

Research shows why breast cancer often metastasizes to lung

Roche's cobas HPV Test gets FDA approval for first-line primary screening for cervical cancer

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

SIOG, EORTC update expert opinion on managing treatment for aged patients with NSCLC

FDA approves Cyramza to treat patients with advanced stomach cancer

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in